TargetBeta
SNAP25
synaptosome associated protein 25 · also SNAP-25, RIC-4, RIC4, SEC9 · SNAREs
3 programs in company-led studies act on SNAP25, from 2 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| botulinum toxin type A | AbbVie | phase 4 | 28613 running | – | the company's pipeline |
| trenibotulinumtoxinErule | AbbVie | phase 3 | 113 running | – | ChEMBL |
| prabotulinumtoxin Arule | AEON Biopharma | phase 3 | 91 running | – | ChEMBL |
Conditions their studies are in
- Migraine Disorders, 2 programs
- Torticollis, 2 programs
- Muscle Spasticity, 1 program
- Stroke, 1 program
- Urinary Bladder, Overactive, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027trenibotulinumtoxinE · AbbVie · phase 3 · NCT07756580
- Mar 2027botulinum toxin type A · AbbVie · phase 4 · NCT07018700
- May 2028prabotulinumtoxin A · AEON Biopharma · phase 3 · NCT07783763
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.